Novo Nordisk shares climb after new CagriSema weight‑loss data
Novo Nordisk reported additional analyses from its REDEFINE 1 trial showing that early responders to the experimental obesity drug CagriSema lost an average of 25.4% of body weight after 68 weeks. The company said 67.8% of participants shed at least 5% of weight within the first eight weeks. Gastro‑intestinal side effects were reported by 79.6% of patients. Novo Nordisk expects a U.S. regulatory decision on CagriSema in the fourth quarter of 2026.
Why it matters
The data could influence investor expectations ahead of the pending U.S. regulatory decision, potentially affecting NVO’s valuation (the company said the decision is expected in Q4 2026).
Key facts
- 1Novo Nordisk shares rose 2.4% after the presentation of the new data. investing.com
- 2Early responders achieved an average weight loss of 25.4% at week 68. finance.yahoo.com
- 367.8% of participants lost at least 5% of body weight within eight weeks. investing.com
- 4Gastrointestinal side effects were reported by 79.6% of CagriSema recipients. finance.yahoo.com
- 5Novo Nordisk expects a U.S. regulatory decision in the fourth quarter of 2026. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.